SSB
NVCR icon

Sandy Spring Bank’s NovoCure NVCR Stock Holding History

Sandy Spring Bank’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-185
Closed -$2.89K – 1312
2024
Q1 		$2.89K Hold
185
– – ﹤0.01% 1014
2023
Q4 		$2.76K Hold
185
– – ﹤0.01% 986
2023
Q3 		$2.99K Hold
185
– – ﹤0.01% 990
2023
Q2 		$7.68K Hold
185
– – ﹤0.01% 889
2023
Q1 		$11.1K Hold
185
– – ﹤0.01% 806
2022
Q4 		$13.6K Sell
185
-50
-21% -$3.76K ﹤0.01% 761
2022
Q3 		$18K Buy
235
+50
+27% +$3.9K ﹤0.01% 696
2022
Q2 		$13K Hold
185
– – ﹤0.01% 781
2022
Q1 		$15K Hold
185
– – ﹤0.01% 778
2021
Q4 		$14K Buy
+185
New +$18.6K ﹤0.01% 841

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sandy Spring Bank's NVCR Position: Q2 2024 in Review

Sandy Spring Bank sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 185 shares — an estimated $2.89K sold.

Sandy Spring Bank first reported a position in NVCR in Q4 2021 and held it in 10 quarters. The position peaked at $18K in Q3 2022. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • Sandy Spring Bank reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • Sandy Spring Bank sold 185 NovoCure shares in Q2 2024, an estimated $2.89K.
  • Sandy Spring Bank first reported a position in NovoCure in Q4 2021 and held it in 10 quarters.
  • Sandy Spring Bank's NovoCure position peaked at $18K in Q3 2022.
  • 236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Sandy Spring Bank's 13F filing for Q2 2024, filed 6 Aug 2024.